Wave Life Sciences Ltd. Q3 2025 Earnings Recap

WVE Q3 2025 November 10, 2025

Wave Life Sciences reported strong advancements in its clinical pipeline during Q3 2025, particularly with WVE-007 demonstrating significant potential for weight loss and improved metabolic health through its unique mechanism of action.

Earnings Per Share Miss

$-0.32 vs $-0.30 est.

-6.7% surprise

Revenue Miss

7608000 vs 16345250 est.

-53.5% surprise

Market Reaction

1-Day -10.31%

5-Day -9.92%

30-Day -3.05%

Key Takeaways

WVE-007 showed impressive dose-dependent reductions in activin E of up to 85%, indicating strong efficacy in its first clinical trial cohorts.
Enrollment in the Enlight trial is progressing well, with over 70 participants and a plan to report on more than 100 by 2026.
Positive feedback from recent presentations at Obesity Week highlights industry recognition for WVE-007's potential to offer a convenient treatment alternative to current therapies.
WVE-006 is advancing as a potential first-in-class treatment for AAT deficiency, differentiating itself through its simple subcutaneous dosing regimen.
The company anticipates delivering multiple key updates in the coming months, reflecting on early impacts on weight loss and metabolic health markers.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit WVE on AllInvestView.

Previous Q2 2025